XtalPi (HKG:2228) expects to return to profit for the first half of 2025, according to a Hong Kong bourse filing Tuesday.
The pharma research firm expects to post at least 50 million yuan in net profit for the six months ended June 30, compared with a loss of 1.24 billion yuan a year ago.
Revenue for the period is expected to rise at least 387% year over year to 500 million yuan, the company said.
XtalPi's financial results are due by the end of August.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.